secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001493152-24-018025
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia
--------------------------------------------------------------------------------

- Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.
- Phase I trial completed under Avance Clinical showed ONP-002 safe and well-tolerated.
- Avance Clinical, a CRO with 20+ years experience, will manage the trial in Australia.
- Oragenics President cites confident execution; CMO highlights Australia's head injury expertise.
- Worldwide annual concussions estimated at 69 million; post-concussion syndrome occurs in up to 20%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/0001493152-24-018025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer